Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury
2 Aug 2020A MAFLD model using the PhysioMimix® core system with PHHs cultured in HEP-Fat medium on the Liver-12 plates induced steatosis, altered gene expression, and shifts in CYP activity (increased CYP1A2, 2C9, 2C19, 2E1 activity; reduced CYP3A4 activity). Fat-loaded hepatocytes showed an increased susceptibility to DILI when treated with Acetaminophen and Ticlopidine (increased LDH, reduced albumin and CYP3A4), but not Methotrexate, supporting mechanistic toxicity profiling in metabolic disease contexts.
Related products
Request Quote for All Products
Drug Metabolism and Safety Toxicity Testing Services
CN BioCN Bio supports R&D efforts via fast-track Drug Metabolism and Safety Toxicity Testing Services that deliver human translatable insights from lead candidates in a few weeks and at lower cost than animal studies. By accessing the Company’s expertise and advanced in vitro liver-on-chip models, these Services enable researchers to step beyond standard in-house laboratory workflows for better informed pre-clinical decisions.
Multi-chip Liver-12 (MPS-LC12) Plates by CN Bio
CN BioMulti-chip Liver-12 consumable plates from CN Bio enable the advanced culture of 12 human 3D liver microtissues under perfusion/plate. Each microtissue recapitulates the functionality and microarchitecture of the human liver to accurately predict drug responses.
In vitro NASH Contract Research Services by CN Bio
CN BioCN Bio supports non-alcoholic steatohepatitis (NASH) therapeutic development via fast-track NASH Contract Research Services. NASH Services enable you to gain instant access to CN Bio’s expertise and one of the most advanced human in vitro models available. Submit lead candidates for screening and receive human translatable data for insightful preclinical candidate prioritization, clinical trial design and optimization.